Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Alpelisib + AZD8186 + Enzalutamide|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AZD8186||PIK3CB inhibitor 8 PIK3CD inhibitor 25||AZD8186 selectively inhibits the activity of PI3Kbeta (PIK3CB) and delta (PIK3CD) in the PI3K/Akt/mTOR signaling pathway, which may result in decreased tumor cell proliferation (PMID: 25514658).|
|Alpelisib||Piqray||BYL719||PIK3CA inhibitor 16||Piqray (Alpelisib) is a selective PIK3CA inhibitor that blocks activation of the PI3K signaling pathway and inhibits tumor growth (PMID: 23726034). Piqray (Alpelisib) is FDA approved in combination with fulvestrant for use in postmenopausal women, and men, with advanced or metastatic hormone receptor (HR)-positive, ERBB2 (HER2)-negative, PIK3CA-mutant breast cancer (FDA.gov).|
|Enzalutamide||Xtandi||MDV3100||Hormone - Anti-androgens 26||Xtandi (enzalutamide) is a second-generation small molecule androgen receptor (AR) inhibitor that inhibits AR signaling, thereby resulting in decreased tumor growth (PMID: 24009414, PMID: 25945058). Xtandi (enzalutamide) is FDA approved for use in patients with castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|